Goldman Sachs Recommends Buying Options Ahead of Healthcare Conference
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Goldman Sachs' option strategists are recommending buying healthcare options ahead of the Goldman Sachs healthcare CEO unscripted conference on January 5.
"Buying January options in healthcare stocks ahead of this event is attractive as one month vs three month term structure is near historical lows, suggesting that the market is not expecting material stock moving catalysts in the coming month," they said.
They highlighted options for Bristol Myers Squibb (NYSE: BMY), Merck & Co. (NYSE: MRK), Celgene (Nasdaq: CELG), Allergan (NYSE: AGN), Watson Pharmaceuticals (NYSE: WPI), Medtronic (NYSE: MDT), Humana (NYSE: HUM), Biogen Idec (Nasdaq: BIIB)
"Buying January options in healthcare stocks ahead of this event is attractive as one month vs three month term structure is near historical lows, suggesting that the market is not expecting material stock moving catalysts in the coming month," they said.
They highlighted options for Bristol Myers Squibb (NYSE: BMY), Merck & Co. (NYSE: MRK), Celgene (Nasdaq: CELG), Allergan (NYSE: AGN), Watson Pharmaceuticals (NYSE: WPI), Medtronic (NYSE: MDT), Humana (NYSE: HUM), Biogen Idec (Nasdaq: BIIB)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
- Dell Technologies (DELL) call put ratio 1 call to 1 put with a focus on expiring August options
- CrowdStrike Holdings Inc. (CRWD) call put ratio 1 call to 1 put into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
